Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...

Use of immune checkpoint inhibitors for cancer was associated with a significant reduction in actinic keratoses in a small study. The effect was greatest in younger patients and those with a history ...

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy. HealthDay News — Patients with cancer aged 65 years and older receiving immune ...

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Immune checkpoint inhibitor (ICI) pneumonitis is a potentially life-threatening immune-related adverse event associated with ICI therapy across various malignancies. ICIs enhance antitumour immunity ...

Use of Ablative Radiotherapy in the Setting of Oligometastatic Disease A retrospective analysis of 3,626 patients treated with ICIs for various malignancies within a single health system was conducted ...

Checkpoint inhibitor-based therapy and ISRT may replace autologous transplant and high-dose chemotherapy in low-risk relapsed cHL, reducing side effects while maintaining EFS outcomes. The CheckMate ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...